Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

20 Sept 2022

Abstract excerpt

STRN-ALK fusion is a rare ALK rearrangement identified in non-small cell lung cancer (NSCLC) patients. Here, we reported a case of lung adenocarcinomas with brain metastasis, harboring STRN-ALK fusion, responded well to ensartinib. This case report could provide more information for the therapeutic strategy selecting of NSCLC patients harboring STRN-ALK fusion.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36290807
DOI: 10.3390/curroncol29100530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case ReportPMID 36290807Read ↗

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung CancerSemantic proximity Read ↗

Case Report of Non–Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to AlectinibSemantic proximity Read ↗

EML4‑ALK fusion gene in non‑small cell lung cancer (Review)Semantic proximity Read ↗

Mixed responses to first‐line alectinib in non‐small cell lung cancer patients with rare ALK gene fusions: A case series and literature reviewSemantic proximity Read ↗

Analysis of Clinical Features and Treatment Strategies in Advanced Lung Adenocarcinoma Patients With Acquired ALK Fusion After Resistance of EGFR-TKIsSemantic proximity Read ↗

Lung Squamous Cell Carcinoma With Anaplastic Lymphoma Kinase Rearrangement and TP53 Co-mutation Treated Successfully with Ensartinib: A Case ReportSemantic proximity Read ↗

[Research Progress of BRAF Fusion in Non-small Cell Lung Cancer].Semantic proximity Read ↗

A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasisSemantic proximity Read ↗

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature reviewSemantic proximity Read ↗

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.Semantic proximity Read ↗

Effective Treatment With Endostar and Crizotinib Sequential Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases Harboring a Novel CLHC1/RNT4 Intergenic Region- ALK FusionSemantic proximity Read ↗

A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.